Begins Coverage on VolitionRx (NYSE:VNRX) assumed coverage on shares of VolitionRx (NYSE:VNRXGet Rating) in a research report issued on Thursday. The firm set a “sell” rating on the stock.

NYSE:VNRX opened at $2.61 on Thursday. The stock has a market capitalization of $140.39 million, a price-to-earnings ratio of -5.02 and a beta of 1.65. The company has a fifty day simple moving average of $2.74. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.23. VolitionRx has a 12 month low of $2.08 and a 12 month high of $4.14.

VolitionRx (NYSE:VNRXGet Rating) last posted its earnings results on Wednesday, March 30th. The company reported ($0.15) EPS for the quarter. The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.03 million. VolitionRx had a negative net margin of 15,827.93% and a negative return on equity of 148.44%. On average, equities research analysts anticipate that VolitionRx will post -0.54 EPS for the current fiscal year.

VolitionRx Company Profile (Get Rating)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.

Featured Stories

Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with's FREE daily email newsletter.